CLINICAL_TRIALS
trial_result
· 2025-05-29
Clinical Trial Update: Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) [Phase 2]
Summary
Phase 2 neoadjuvant trial of pembrolizumab in PD-1-naive cutaneous squamous cell carcinoma. Results have been posted in May 2025.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Diwakar Davar | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-05-29